Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals is a high-tech biotech company providing integrated research and development services for innovative biologic drugs. Its platform spans from target identification to clinical sample production, powered by an AI-driven super-trillion antibody library and a drug accelerator combining dry-lab and wet-lab capabilities. The company operates through four business models: CRO, CDO, CPO, and CRS.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
Funding
Raised to date
CN¥100MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $13.9Macross 1 round
CN¥100M · Series C
Announced Nov 2026 · from article date
Disclosed cumulative: $13.9M
Founders
Founder details are not available yet.
Product
Problem
Developing innovative biologic drugs is a complex, time-consuming process that requires expertise across multiple disciplines, from target discovery through clinical manufacturing. Biotech and pharmaceutical companies often lack the specialized infrastructure, proprietary technologies, and integrated capabilities needed to efficiently advance drug candidates from concept to clinical trials.
Solution
Sanyou Biopharmaceuticals provides an integrated service platform covering the entire biologic drug development journey, from "target to PCC molecule," "PCC molecule to IND application," and "IND application to clinical sample production." The company leverages its AI-Super-Trillion Antibody Library (AI-STAL) as a source of innovation and its Sanyou AI-Drug Accelerator (SAI-DA), which integrates dry-lab and wet-lab workflows, as a core engine. This open innovation system, called Clicklinks, is driven by new drug pipelines to accelerate the translation of discoveries into therapies for patient populations. The platform encompasses 10 major functional modules and over 50 sub-platforms, including raw material preparation, antibody generation, in vitro functional assays, antibody engineering, in vivo efficacy evaluation, druggability analysis, production cell line development, process development, quality control, and pilot-scale experiments.
Target Audience
Primary customers are biopharmaceutical and biotechnology companies seeking outsourced research and development services for innovative biologic drugs, including antibody discovery, engineering, preclinical development, and clinical manufacturing.
Features
- AI-Super-Trillion Antibody Library (AI-STAL) providing a world-leading source of antibody diversity for drug discovery
- Sanyou AI-Drug Accelerator (SAI-DA) integrating computational (dry-lab) and experimental (wet-lab) approaches to streamline drug development
- Clicklinks open innovation system connecting drug pipelines with development services
- 10 major functional modules and 50+ sub-platforms covering the full spectrum from target identification to clinical sample production
- ISO9001 quality management and ISO27001 information security certifications
- 20,000+ m² of integrated R&D laboratory space with 3,000+ project experience